Program
Timolol
Also written as “Timolol Maleate Gel”, “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)” and “timolol 0.5%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Hemangioma, Capillary, led by 9 companies.
Drug pageTimolol: every studyMany companies study it; this page follows only the 23 they lead. All 84 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 80 open or running | phase 4since Aug 13, 2008 | Aug 13, 2008 | none ahead |
| Merckits history only | 30 open or running | phase 3since Apr 12, 2005 | Apr 12, 2005 | none ahead |
| Santen Pharmaceuticalits history only | 30 open or running | phase 3since Feb 28, 2011 | Apr 7, 2009 | none ahead |
| Viatrisits history only | 30 open or running | phase 3since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Auson Pharmaceuticalsits history only | 20 open or running | phase 3since Oct 29, 2024 | Oct 29, 2024 | none ahead |
| Credit Valley EyeCareits history only | 10 open or running | phase 4since Feb 13, 2012 | Feb 13, 2012 | none ahead |
| Glaukosits history only | 10 open or running | phase 4since Jun 1, 2009 | Jun 1, 2009 | none ahead |
| Laboratorios Poenits history only | 10 open or running | phase 4since Mar 30, 2023 | Mar 30, 2023 | none ahead |
| Vistakon Pharmaceuticalsits history only | 10 open or running | phase 4since Dec 5, 2008 | Dec 5, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Apr 12, 2005.
- Jun 1, 2009Glaukos’ first study: phase 4 study in Eye DiseasesNew to GlaukosGlaukos · NCT00913029 · 192 enrolled · Armenia, Austria, France and more
- Feb 12, 2010No phase study in Glaucoma, Open-AngleAbbVie · NCT01068964 · 235 enrolled · China
- Oct 5, 2010Phase 1 study in Glaucoma, Open-AngleAbbVie · NCT01215786 · 50 enrolled · United States
- Oct 7, 2010Phase 3 study in Glaucoma, Open-AngleAbbVie · NCT01217606 · 185 enrolled · Brazil
- Oct 26, 2010No phase study in GlaucomaAbbVie · NCT01229462 · 238 enrolled · China
- Nov 12, 2010Phase 3 study in Glaucoma, Open-AngleAbbVie · NCT01241240 · 192 enrolled · Colombia, Mexico
- Feb 28, 2011Phase 3 study in Ocular HypertensionSanten Pharmaceutical · NCT01306461 · 401 enrolled · Hungary
- Sep 12, 2011Phase 1 study in Healthy VolunteersSanten Pharmaceutical · NCT01434888 · 15 enrolled · Finland
- Feb 13, 2012Credit Valley EyeCare’s first study: phase 4 study in GlaucomaNew to Credit Valley EyeCareCredit Valley EyeCare · NCT01535768 · 150 enrolled · Canada
- Jun 17, 2013Phase 4 study in GlaucomaAbbVie · NCT01881126 · 93 enrolled · Canada
- Mar 25, 2014Phase 4 study in GlaucomaAbbVie · NCT02097719 · 100 enrolled · United States
- Mar 30, 2023Laboratorios Poen’s first study: phase 4 study in Glaucoma, Open-AngleNew to Laboratorios PoenLaboratorios Poen · NCT05857267 · 84 enrolled · Argentina
- Oct 29, 2024Auson Pharmaceuticals’ first study: phase 3 study in Hemangioma, CapillaryNew to Auson PharmaceuticalsAuson Pharmaceuticals · NCT06677853 · 168 enrolled · China
- Jan 23, 2025Phase 1 study in Healthy SubjectsAuson Pharmaceuticals · NCT06824948 · 28 enrolled · China
TargetBeta
“Beta-1 adrenergic receptor antagonist; Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06824948Healthy Subjects · China | 1 | Completed | Auson Pharmaceuticals | Dec 12, 2018 | 28 |
| NCT06677853Hemangioma, Capillary · China | 3 | Completed | Auson Pharmaceuticals | Jun 21, 2022 | 168 |
| NCT05857267Glaucoma, Open-Angle · Argentina | 4 | Completed | Laboratorios Poen | Nov 4, 2024 | 84 |
| NCT02097719Glaucoma · United States | 4 | Completed | AbbVie | Dec 2014 | 100 |
| NCT01881126Glaucoma · Canada | 4 | Completed | AbbVie | Oct 2014 | 93 |
| NCT01535768Glaucoma · Canada | 4 | UNKNOWN | Credit Valley EyeCare | Jun 2018 | 150 |
| NCT01434888Healthy Volunteers · Finland | 1 | Completed | Santen Pharmaceutical | Dec 2011 | 15 |
| NCT01306461Ocular Hypertension · Hungary | 3 | Completed | Santen Pharmaceutical | Apr 2012 | 401 |
| NCT01241240Glaucoma, Open-Angle · Colombia, Mexico | 3 | Completed | AbbVie | Sep 2013 | 192 |
| NCT01229462Glaucoma · China | – | Completed | AbbVie | Sep 2011 | 238 |
| NCT01217606Glaucoma, Open-Angle · Brazil | 3 | Completed | AbbVie | Sep 2014 | 185 |
| NCT01215786Glaucoma, Open-Angle · United States | 1 | Completed | AbbVie | Dec 2010 | 50 |
| NCT01068964Glaucoma, Open-Angle · China | – | Completed | AbbVie | Sep 1, 2010 | 235 |
| NCT00913029Eye Diseases · Armenia, Austria, France and more | 4 | Completed | Glaukos | Sep 2012 | 192 |
| NCT00879099Healthy · Finland | 1 | Completed | Santen Pharmaceutical | Jan 2010 | 12 |
| NCT00856622Ocular Hypertension · Germany | 3 | Completed | Viatris | Jun 1999 | 436 |
| NCT00832377Glaucoma | 2 | Completed | Merck | Mar 12, 2010 | 37 |
| NCT00804648Glaucoma, Open-Angle · United States | 4 | Completed | Vistakon Pharmaceuticals | Dec 2008 | 30 |
| NCT00735449Glaucoma · United States, Canada | 4 | Completed | AbbVie | Dec 2009 | 204 |
| NCT00546286Glaucoma | 3 | Completed | Merck | Aug 23, 2007 | 170 |
| NCT00277498Glaucoma, Open-Angle · United States | 3 | Completed | Viatris | 528 | |
| NCT00159653Glaucoma, Open-Angle · United States, Canada | 3 | Completed | Viatris | Jun 2007 | 500 |
| NCT00108017Glaucoma | 3 | Completed | Merck | Jul 2006 | 330 |
How it is read
Names in the registry
- “Timolol Maleate Gel”, 4 entries
- “Timolol”, 3 entries
- “bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)”, 2 entries
- “timolol 0.5%”, 2 entries
- “timolol maleate”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 14 studies
- Glaucoma, 9 studies
- Hemangioma, Capillary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.